IBM Watson Health's clinical support in cancer care proven by multiple studies

IBM Watson Health and its partners presented a total of 22 new studies demonstrating the artificial intelligence technology's real-world potential in the field of oncology at the American Society for Clinical Oncology's annual meeting on May 31.

In one of the studies, Watson for Oncology AI trained by New York City's Memorial Sloan Kettering Cancer Center influenced changes in the treatment plans of 13.6 percent of breast, lung and colorectal cancer patients in India. The majority of those cases were altered after Watson identified and suggested newer treatments or more personalized alternatives to the multidisciplinary tumor board at Bengaluru-based Manipal Hospitals.

Another study incorporated Watson for Oncology into the patient engagement and consultation process at the Beijing Chaoyang Integrative Medicine Emergency Medical Center's oncology department. Physicians reported that the AI helped patients better understand their diagnosis and treatment options, resulting in greater patient confidence in their care plans.

"In this early era of AI use in healthcare decision-making, the studies presented at ASCO this year offer compelling evidence of the important role this technology will play in helping oncologists improve cancer treatment for each individual patient," Nathan Levitan, MD, chief medical officer for oncology and genomics at IBM Watson Health, said in a statement.

More articles about AI:
Startup using AI, AR to detect Alzheimer's 10 years before onset raises $6.3M
Precision medicine startup Tempus raises $200M to reach $3.1B valuation
MIT-developed AI glove teaches robots to 'feel,' could improve prosthetics

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months